P8IP
IOVA icon

Pier 88 Investment Partners’s Iovance Biotherapeutics IOVA Stock Holding History

Pier 88 Investment Partners’s Portfolio IOVA Stock Details IOVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-10
Closed -$27 – 118
2025
Q4 		$27 Hold
10
– – ﹤0.01% 117
2025
Q3 		$22 Sell
10
-300
-97% -$708 ﹤0.01% 113
2025
Q2 		$533 Sell
310
-126,630
-100% -$315K ﹤0.01% 104
2025
Q1 		$423K Buy
126,940
+72,310
+132% +$373K 0.08% 89
2024
Q4 		$404K Buy
54,630
+10,450
+24% +$96.9K 0.08% 86
2024
Q3 		$415K Sell
44,180
-14,400
-25% -$136K 0.09% 78
2024
Q2 		$470K Buy
58,580
+35,680
+156% +$382K 0.11% 80
2024
Q1 		$339K Sell
22,900
-4,390
-16% -$51.1K 0.08% 78
2023
Q4 		$222K Buy
+27,290
New +$143K 0.06% 80
2021
Q4 		– Sell
-6,650
Closed -$164K – 117
2021
Q3 		$164K Buy
6,650
+5,030
+310% +$119K 0.05% 106
2021
Q2 		$42K Sell
1,620
-15,706
-91% -$408K 0.01% 110
2021
Q1 		$549K Sell
17,326
-3,165
-15% -$131K 0.19% 89
2020
Q4 		$951K Sell
20,491
-19,990
-49% -$794K 0.31% 71
2020
Q3 		$1.33M Buy
40,481
+29,256
+261% +$897K 0.4% 51
2020
Q2 		$308K Buy
11,225
+2,035
+22% +$66.9K 0.09% 96
2020
Q1 		$275K Buy
+9,190
New +$244K 0.1% 86

Other funds holding IOVA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
MFM
MHR Fund Management New York $1.92B AUM 119.57% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
ICM
Invenomic Capital Management Boston, Massachusetts $1.67B AUM 1.43% 1-Year Est. Return

Pier 88 Investment Partners's IOVA Position: Q1 2026 in Review

Pier 88 Investment Partners sold out of Iovance Biotherapeutics (IOVA) in Q1 2026, closing a stake of 10 shares — an estimated $27 sold.

Pier 88 Investment Partners first reported a position in IOVA in Q1 2020 and held it in 16 quarters. The position peaked at $1.33M in Q3 2020. 286 funds tracked by Wall St. Rank hold IOVA as of Q1 2026.

  • Pier 88 Investment Partners reported no remaining Iovance Biotherapeutics position as of Q1 2026 after selling out during the quarter.
  • Pier 88 Investment Partners sold 10 Iovance Biotherapeutics shares in Q1 2026, an estimated $27.
  • Pier 88 Investment Partners first reported a position in Iovance Biotherapeutics in Q1 2020 and held it in 16 quarters.
  • Pier 88 Investment Partners's Iovance Biotherapeutics position peaked at $1.33M in Q3 2020.
  • 286 funds tracked by Wall St. Rank held Iovance Biotherapeutics as of Q1 2026.

Based on Pier 88 Investment Partners's 13F filing for Q1 2026, filed 11 May 2026.